Arrhythmias in COVID-19: New Review Tackles Mechanisms, Management
The virus or its treatments may disrupt heart rhythm, but the immune response and its targets likely deserve the most scrutiny.
The virus or its treatments may disrupt heart rhythm, but the immune response and its targets likely deserve the most scrutiny.
The findings suggest these types of patients continue to improve beyond 3-6 months and thus might benefit from longer rehab.
Although ORBITA-AF shows it can be done, and other trials are underway, not everyone is convinced it’s worth the effort.
It’s possible that other classes of antithrombotics may be worth adding to improve reperfusion, but that’s conjecture right now.
”Zero-degree positioning” may be one of the most important first steps in managing large vessel occlusions, study shows.
The findings shouldn’t, however, discourage those who want children from pursuing ART, experts say.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
Initial safety and efficacy findings from this first-in-human series “look really impressive,” but experts await further studies.
In an EHRA debate, experts grappled with how to interpret promising preliminary data while longer-term trials are ongoing.
As demand for the drug continues to rise, alternatives like the oral formulation and other injectable GLP-1s come into play.
The first-in-human results represent “an encouraging first step with a novel ablation source,” one expert says.